IRCT2016102730410N2
Completed
Phase 2
A novel protocol for anti coagulation therapy after coronary endarterectomy in coronary artery bypass graft patients
Babol University of Medical Sciences, Deputy of Research & Technology0 sites55 target enrollmentTBD
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Coronary artery disease.
- Sponsor
- Babol University of Medical Sciences, Deputy of Research & Technology
- Enrollment
- 55
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •inclusion criteria: patients undergoing Cronary artery bypass graft / coronary endarterectomy
- •Exclusion criteria were as follows : need to concomitant valve surgery ; history of allergic reaction to Asprin and Plavix; any systemic disease
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Development of antiplatelet therapy protocol for coil embolization of intracranial aneurysmDiseases of the nervous systemKCT0000804Seoul National University Bundang Hospital290
Recruiting
Not Applicable
Anticoagulation therapy around catheter ablation for atrial fibrillation -Dabigatran vs. WarfarinAtrial fibrillationJPRN-UMIN000006907DAWN-AF-Trial Society100
Recruiting
Phase 1
The effect of coagulation factors on the reduction of joint/ non-joint bleeding and the consumption of coagulation factor in patients with severe A hemophiliaHemophilia.Hereditary factor VIII deficiencyIRCT20170211032495N1Vice chancellor for research of Tehran University of Medical Sciences15
Active, not recruiting
Phase 1
Anticoagulant Regimens Given to achieve thrombus regression and reduce clinical Outcomes among patients with Non device-related intra-cardiac thrombus: a randomized Assessment Under direct oral anticoagulant and vitamin K antagonist Therapy – the ARGONAUT trialintra-cardiac thrombusMedDRA version: 20.0Level: PTClassification code: 10048620Term: Intracardiac thrombus Class: 100000004849Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]CTIS2024-512685-33-00Centre Hospitalier Universitaire De Nimes340
Completed
Not Applicable
Controlled Anti-platelet medical therapy based on rapid CYP2C19 gene evaluation in Acute myocardial infarctioAcute myocardial infarctionJPRN-UMIN000008151Graduate School of Medical Sciences, Kumamoto University100